ArticleKidney international reports2026
Randomized Double-Blind Trial of WS016 in Chinese Patients With Hyperkalemia.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: WS016 is a highly selective cation exchanger which traps potassium in the intestinal tract, reducing serum potassium levels in patients with hyperkalemia. This study aimed to evaluate the efficacy and safety of WS016 in hyperkalemic patients. Methods: One hundred forty eligible patients were randomized to receive either WS016 (3 g, 6 g, or 12 g), thrice daily, or placebo for 48 hours. Among those who achieved normokalemia, patients were randomized to WS016 (3 g, 6 g, and 12 g), once daily for 12 days. The primary outcome was the exponential rate of change in serum potassium levels from baseline over the acute and maintenance treatment period, respectively. Results: During the acute treatment phase, the mean exponential rates of reduction from baseline were 0.19% ( Conclusion: WS016 reduced serum potassium levels rapidly and maintained more patients within the normokalemic range.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.